ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,127.45
-0.96%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Adverum Biotechnologies Inc (ADVM)

  7. Adverum Biotechnologies Inc (ADVM) Noticias

ADVM Adverum Biotechnologies Inc

9.19
-0.20 (-2.13%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Adverum Biotechnologies Inc ADVM NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.20 -2.13% 9.19 15:36:37
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
9.60 9.11 10.10 9.19 9.39
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202415:05GLOBEAdverum Biotechnologies to Present LUNA 26-week Phase 2..
18/3/202415:05GLOBEAdverum Biotechnologies Reports Fourth Quarter and Full Year..
04/3/202415:40EDGAR2Form S-3 - Registration statement under Securities Act of..
28/2/202415:05GLOBEAdverum Biotechnologies to Participate in the TD Cowen 44th..
22/2/202414:47EDGAR2Form SC 13G - Statement of acquisition of beneficial..
21/2/202414:39EDGAR2Form D - Notice of Exempt Offering of Securities
15/2/202415:17EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202419:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202415:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202415:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202415:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202415:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202407:00GLOBEAdverum Biotechnologies to Participate in the Oppenheimer..
09/2/202416:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202410:41EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/2/202407:45EDGAR2Form 8-K - Current report
08/2/202406:00GLOBEAdverum Biotechnologies Announces Positive Preliminary..
06/2/202415:47EDGAR2Form 8-K - Current report
05/2/202416:03EDGAR2Form 8-K - Current report
05/2/202406:45GLOBEAdverum Biotechnologies Announces $127.5 Million Private..
01/2/202416:30GLOBEAdverum Biotechnologies will Host Webcast to Review LUNA..
29/1/202407:00GLOBEAdverum Biotechnologies Appoints Romuald Corbau, Ph.D. as..
08/12/202315:11EDGAR2Form 8-K - Current report
07/12/202315:05GLOBEAdverum Biotechnologies to Present LUNA Preliminary Efficacy..
04/12/202315:09EDGAR2Form 8-K/A - Current report: [Amend]
28/11/202315:05GLOBEAdverum Biotechnologies to Participate in the Evercore ISI..
09/11/202315:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202315:07EDGAR2Form 8-K - Current report
09/11/202315:05GLOBEAdverum Biotechnologies Reports Third Quarter 2023 Financial..
06/11/202318:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/11/202318:52EDGAR2Form 3 - Initial statement of beneficial ownership of..
06/11/202315:10EDGAR2Form 8-K - Current report
06/11/202307:00GLOBEAdverum Biotechnologies Appoints C. David Nicholson, Ph.D...
04/11/202316:54GLOBEAdverum Biotechnologies Announces 3-Year Efficacy and Safety..
26/9/202315:05GLOBEAdverum Biotechnologies Announces Positive Aflibercept..
21/9/202315:05GLOBEAdverum Biotechnologies to Participate in Upcoming Investor..
18/9/202317:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202315:05GLOBEAdverum Biotechnologies to Participate in the H.C...
21/8/202315:05GLOBEAdverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as..
14/8/202307:00GLOBEAdverum Biotechnologies to Participate in the H.C...
10/8/202315:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202315:09EDGAR2Form 8-K - Current report
10/8/202315:05GLOBEAdverum Biotechnologies Completes Enrollment of Phase 2 LUNA..
04/8/202315:18EDGAR2Form 8-K - Current report
24/7/202315:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/6/202307:00GLOBEAdverum Biotechnologies Grants License to Ray Therapeutics..
02/6/202307:00GLOBEAdverum Biotechnologies to Participate in the Jefferies..
25/5/202305:30GLOBEAdverum Biotechnologies Announces New Executive Leadership..
18/5/202308:00GLOBEAdverum Biotechnologies Presents Nonclinical Data in Support..
11/5/202315:05GLOBEAdverum Biotechnologies Reports First Quarter 2023 Financial..

Su Consulta Reciente

NASDAQ
ADVM
Adverum Biotechnologies
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados